Faruqi Shoaib, Murdoch Robert D, Allum Fabrice, Morice Alyn H
Department of Cardiovascular and Respiratory Studies, University of Hull and the Hull York Medical School, Castle Hill Hospital, Cottingham, UK.
Respiratory Discovery Medicine, GlaxoSmithKline, Stevenage, UK.
Cough. 2014 May 29;10:5. doi: 10.1186/1745-9974-10-5. eCollection 2014.
The pathogenesis of chronic cough is not well understood and treatment options are limited. In this study we sought to explore the current understanding and management of chronic cough across an international group of specialists.
This was an international study of cross sectional qualitative design. In depth interviews were carried out with "Respiratory Specialists" experienced in treating treating Chronic Obstructive Pulmonary Disease (COPD), idiopathic pulmonary fibrosis (IPF), idiopathic chronic cough (ICC) and/or lung cancer patients and with "Disease Experts" in the field of Chronic Cough. Participants in the study were recruited from the USA, UK, Germany, Ireland, Australia and Japan. Interviews with specialists were held at research facilities and with DEs over the telephone. These were preceded by the specialists completing case records of patients recently seen. All interviews were conducted by native speaking trained moderators using a semi-structured interview guide script. This was designed to elicit the definition of chronic cough, explore the unmet needs for each disease state, define therapy goals, identify patient phenotypes and give an overview of the treatment pathway.
76 specialists and 10 experts took part in the study. Over two thirds (70%) of respondents defined chronic cough as "cough lasting more than 8/12 weeks" (range 2 weeks to 2 years). Physicians emphasised three interdependent aspects of clinical assessment: impact on quality of life, type of cough (productive versus non-productive) and the underlying pathology. Specialists emphasised treating the underlying cause rather than the cough, this being most prominent in Japan. Experts as a group focussed on chronic cough independently. Evaluation of the respiratory system, GI tract and upper airway (ENT) for establishing an underlying cause was recommended. Type of cough (productive vs non-productive) and impact on quality of life influenced treatment initiation. 33% of patients with ICC were prescribed anti-tussives. With associated diagnoses of COPD, IPF or lung cancer the emphasis was on treating the underlying condition. Alternatives to pharmacological treatments were frequently considered.
There is significant international variation in our understanding and management of chronic cough. Further work is required to bring forth clear guidance and effective medicines for these patients.
慢性咳嗽的发病机制尚未完全明确,治疗选择有限。在本研究中,我们试图探究国际专家组对慢性咳嗽的当前认识及管理情况。
这是一项采用横断面定性设计的国际研究。对治疗慢性阻塞性肺疾病(COPD)、特发性肺纤维化(IPF)、特发性慢性咳嗽(ICC)和/或肺癌患者的“呼吸科专家”以及慢性咳嗽领域的“疾病专家”进行了深入访谈。研究参与者来自美国、英国、德国、爱尔兰、澳大利亚和日本。与专家的访谈在研究机构进行,与疾病专家的访谈通过电话进行。在此之前,专家们需完成近期诊治患者的病例记录。所有访谈均由母语为英语的专业主持人使用半结构化访谈指南脚本进行。该脚本旨在引出慢性咳嗽的定义,探索每种疾病状态未满足的需求,确定治疗目标,识别患者表型,并概述治疗途径。
76名专家和10名专家参与了该研究。超过三分之二(70%)的受访者将慢性咳嗽定义为“咳嗽持续超过8/12周”(范围为2周至2年)。医生们强调了临床评估的三个相互关联的方面:对生活质量的影响、咳嗽类型(有痰性咳嗽与无痰性咳嗽)以及潜在病理状况。专家们强调治疗潜在病因而非咳嗽本身,这在日本最为突出。专家群体则独立关注慢性咳嗽。建议对呼吸系统、胃肠道和上呼吸道(耳鼻喉科)进行评估以确定潜在病因。咳嗽类型(有痰性咳嗽与无痰性咳嗽)以及对生活质量的影响会影响治疗的启动。33%的ICC患者被开具了镇咳药。对于合并COPD、IPF或肺癌诊断的患者,重点在于治疗潜在疾病。人们经常考虑药物治疗的替代方法。
我们对慢性咳嗽的认识和管理在国际上存在显著差异。需要进一步开展工作,为这些患者提供明确的指导和有效的药物。